HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bailing Xu Selected Research

Zj6413

5/2016Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bailing Xu Research Topics

Disease

6Neoplasms (Cancer)
09/2023 - 10/2013
2Alzheimer Disease (Alzheimer's Disease)
01/2022 - 01/2007
2Breast Neoplasms (Breast Cancer)
11/2021 - 05/2016
1Fibrosis (Cirrhosis)
09/2023
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2022
1Inflammation (Inflammations)
01/2022
1Glioblastoma (Glioblastoma Multiforme)
11/2021
1Triple Negative Breast Neoplasms
05/2016
1Neoplasm Metastasis (Metastasis)
05/2016

Drug/Important Bio-Agent (IBA)

2Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2022 - 05/2016
1Galectin 3 (LGALS3)IBA
09/2023
1Oxidoreductases (Dehydrogenase)IBA
01/2022
1Biogenic Amines (Biogenic Amine)IBA
01/2022
1Monoamine Oxidase (MAO)IBA
01/2022
1N-dodecyl-L-lysine amideIBA
11/2021
1Peptidylprolyl Isomerase (Prolyl Isomerase)IBA
01/2021
1Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA
02/2020
1Tryptophan Oxygenase (Tryptophan 2,3 Dioxygenase)IBA
02/2020
1Tryptophan (L-Tryptophan)FDA Link
02/2020
1Temozolomide (Temodar)FDA LinkGeneric
05/2016
1DNA (Deoxyribonucleic Acid)IBA
05/2016
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
05/2016
1Proteins (Proteins, Gene)FDA Link
05/2016
1Zj6413IBA
05/2016
1OxazolesIBA
10/2013
1NitrogenIBA
10/2013
1fosbretabulin (combretastatin A4)IBA
10/2013
1imidazoleIBA
10/2013
1Amyloid beta-PeptidesIBA
01/2007

Therapy/Procedure

1Drug Therapy (Chemotherapy)
01/2022
1Immunotherapy
02/2020